In the clinic, anti-estrogen therapy including selective ER modulators (SERMs), selective ER down-regulators (SERDs), and aromatase inhibitors (AIs) is the standard of care for patients with ERα+ breast cancers (Siersbaek et al., 2018). Here, ESR1 is linked to breast cancer.